Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Dieter Saur

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5874-0210; OpenAlex author ID A5090240499. Sources: OpenAlex.

Their work

Papers
69 (first author 3, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
266
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 7 papers · 2019: 1 paper · 2020: 4 papers · 2021: 5 papers · 2022: 10 papers · 2023: 6 papers · 2024: 5 papers · 2025: 6 papers · 2026: 11 papers

Papers 50 of 69

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  3. Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. Co-author DOI 10.1016/j.xcrm.2025.102546↗
  4. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  5. Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.08.018↗
  6. Neutrophil-Driven Trogocytosis in Pancreatic Ductal Adenocarcinoma Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic P… Co-author DOI 10.1053/j.gastro.2026.04.021↗
  7. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Co-author DOI 10.1158/2767-9764.crc-25-0670↗
  8. Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci206371↗
  9. Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancer Last author DOI 10.64898/2026.03.19.712924↗
  10. Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model Co-author DOI 10.64898/2026.06.26.734719↗
  11. MYC/MIZ1 suppression of lysosomal protein degradation drives immune evasion in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.07.23.740267↗
  12. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  13. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  14. Pancreatic cancer cells infiltrate nerves through TGFbeta1-driven perineural epithelial-to-mesenchymal-like transdifferentiation. Co-author DOI 10.1016/j.neo.2025.101126↗
  15. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  16. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  17. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci177533↗
  18. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  19. The Janus kinase 1 is critical for pancreatic cancer initiation and progression. Co-author DOI 10.1016/j.celrep.2024.114202↗
  20. Coexisting mechanisms of luminogenesis in pancreatic cancer-derived organoids. Co-author DOI 10.1016/j.isci.2024.110299↗
  21. Exosomes define a local and systemic communication network in healthy pancreas and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-45753-7↗
  22. Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. Co-author DOI 10.1136/gutjnl-2023-331519↗
  23. Epigenetic control of pancreatic cancer metastasis. Co-author DOI 10.1007/s10555-023-10132-z↗
  24. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Co-author DOI 10.1038/s41388-023-02716-4↗
  25. Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation. Co-author DOI 10.1038/s41467-023-38171-8↗
  26. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Last author DOI 10.1038/s43018-023-00526-x↗
  27. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-22-0876↗
  28. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  29. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  30. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  31. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Last author DOI 10.1038/s43018-021-00326-1↗
  32. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1053/j.gastro.2022.02.024↗
  33. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2020-321397↗
  34. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  35. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment. Co-author DOI 10.1158/0008-5472.can-20-3807↗
  36. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  37. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  38. Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer. First author DOI 10.3791/64253↗
  39. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Co-author DOI 10.1053/j.gastro.2020.09.010↗
  40. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  41. Rationale for MYC imaging and targeting in pancreatic cancer. Last author DOI 10.1186/s13550-021-00843-1↗
  42. Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. Co-author DOI 10.15252/emmm.202013502↗
  43. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Co-author DOI 10.7554/elife.55117↗
  44. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Co-author DOI 10.1002/1878-0261.12835↗
  45. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  46. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  47. Blocking the road to de-differentiation: HNF1A/KDM6A complex safeguards epithelial integrity in pancreatic cancer. Last author DOI 10.15252/embj.2020104759↗
  48. Metastasis of pancreatic cancer: An uninflamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreati… Co-author DOI 10.1016/j.canlet.2019.03.039↗
  49. Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.26847↗
  50. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelia… Co-author DOI 10.1016/j.canlet.2017.12.004↗

Closest collaborators

The 25 strongest of 266 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Günter Schneider · 40 shared papers, 2011–2026 · strength 4.37
  2. Roland Rad · 29 shared papers, 2014–2026 · strength 3.69
  3. Maximilian Reichert · 25 shared papers, 2013–2026 · strength 3.01
  4. Stefanie Bärthel · 13 shared papers, 2020–2026 · strength 2.41
  5. Matthias Wirth · 18 shared papers, 2011–2026 · strength 2.07
  6. Roland Michael Schmid · 23 shared papers, 2011–2026 · strength 2.00
  7. Chiara Falcomatà · 11 shared papers, 2021–2026 · strength 1.79
  8. Christian Schneeweis · 13 shared papers, 2018–2026 · strength 1.77
  9. Lukas Krauß · 9 shared papers, 2022–2026 · strength 1.42
  10. Carolin Schneider · 9 shared papers, 2022–2026 · strength 1.42
  11. Elisabeth Heßmann · 8 shared papers, 2021–2026 · strength 1.37
  12. İhsan Ekin Demir · 7 shared papers, 2022–2026 · strength 1.18
  13. Felix Orben · 8 shared papers, 2020–2026 · strength 1.00
  14. Daniele Lucarelli · 5 shared papers, 2022–2026 · strength 0.92
  15. Michael B. Ghadimi · 5 shared papers, 2024–2026 · strength 0.92
  16. Carmen Mota Reyes · 5 shared papers, 2023–2026 · strength 0.90
  17. Oliver Holger Krämer · 10 shared papers, 2011–2026 · strength 0.90
  18. Marian Grade · 5 shared papers, 2022–2026 · strength 0.83
  19. Guralp Onur Ceyhan · 6 shared papers, 2018–2026 · strength 0.82
  20. Zonera Hassan · 9 shared papers, 2017–2022 · strength 0.82
  21. Volker Ellenrieder · 5 shared papers, 2021–2026 · strength 0.80
  22. Ulrich Bernd Keller · 5 shared papers, 2020–2026 · strength 0.77
  23. Constanza Tapia Contreras · 4 shared papers, 2024–2026 · strength 0.71
  24. Helmut Friess · 4 shared papers, 2022–2026 · strength 0.69
  25. Takahisa Maruno · 4 shared papers, 2021–2026 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.